RECELL® System Data to be Presented at the American Burn Association Annual Meeting
04 avr. 2022 08h00 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, April 04, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
23 mars 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
21 mars 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
02 mars 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
28 févr. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and...
The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
23 févr. 2022 16h29 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
23 févr. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
17 févr. 2022 16h01 HE
|
AVITA Medical
System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022 VALENCIA, Calif. and MELBOURNE,...
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
15 févr. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
02 févr. 2022 16h01 HE
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...